Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2007

View Archived Issues

New experimental and clinical data on lacosamide presented

Novel agents for treating endocrine-associated disorders disclosed in recent patent literature

Recent patents disclose new therapeutic agents for neurological disorders

VGX signs DNA vaccines license agreement with U. of Pennsylvania

Kyowa Hakko Kogyo licenses Japanese and Asian rights to ARQ-197

SciClone acquires rights in U.S. and Canada to RP-101

Elan reviews quarterly progress

New phase II trial for Avugane in acne vulgaris

York Pharma acquires Rosanto

Acropolis reports on PA-105, an antiangiogenic agent with antiprostate cancer activity

EMEA will not approve Cerepro at this time

Meda acquires product portfolio from Wyeth

Enrollment completed in phase I/II study of BDM-E for diabetic macular edema

E.U. positive opinion for PegIntron and Rebetol for HCV in HIV subjects

VR-004 achieves erectile dysfunction endpoints in phase IIb trial

CDC25 phosphatase inhibition with IRC-083864 suppresses tumor growth in vitro and in vivo

CDK inhibitor SNS-032 induces apoptosis in multiple myeloma cells

GSK-461364, a potent, selective small-molecule PLK1 inhibitor selected for further development

Acceptable safety profile emerges from early clinical trial with masitinib

Tolvaptan improves patient-reported health outcomes in hyponatremic patients

Sebivo receives E.U. approval

Approval for once-daily Veramyst nasal spray

Invega approved for long-term maintenance treatment of schizophrenia

Soliris recommended for European approval in PNH

FDA approves AzaSite for bacterial conjunctivitis

Recent Gedeon Richter and Glenmark patents disclose novel analgesic agents

Telavancin filed for European approval for cSSTI

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...